
Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients
Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared a post on X:
“Two phase 1 trials published in Nature Medicine (IBI343 and SHR-A1904) tested CLDN18.2-targeting ADCs in heavily pretreated, refractory advanced gastric/GEJ cancer patients with no standard options left. Both drugs showed ORR of 25–29% and PFS of ~5.5–5.8 months.
Ongoing phase 3 studies will further define their role in treatment…”
Title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
Authors: Jia Liu, Jianwei Yang, Yuping Sun, Jifang Gong, Jinbo Yue, Yueyin Pan, Meili Sun, Rongfeng Song, Xiuying Xiao, Andrea Tazbirkova, Jian Ruan, Zhenyang Liu, Zimin Liu, Zhihua Li, Lili Sheng, Yanru Qin, Jieer Ying, Xianjun Yu, Jian Zhang, Yiping Mou, Chuangxin Lu, Ping Chen, Suyi Li, Jie Li, Xiujuan Qu, Ting Deng, Juan Du, Aiping Zhou, Enxiao Li, Xianglin Yuan, Xinjun Liang, Weiming Yu, Michelle Morris, Yang Luo, Xin Zhao, Yingmei Guo, Hui Zhou, Lin Shen
You can read the Full Article in the Nature Medicine.
Title: The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
Authors: Dan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, Wen-Wen Huang, Xin-Jun Liang, Zuo-Xing Niu, Qi Dang, Hong-Li Li, Zhan-Yu Pan, Hong-Xia Lu, Yan-Qiao Zhang, Xing-Ya Li, Xiu-Ying Xiao, Shi-Rong Cai, Yu-Gang Dong, Jian Zhang, Zhou Li, Hai-Tao Lan, Xin Wang, Ying Zhou, Lian Liu, He-Li Liu, Ping-Sheng Xu, Ai-Li Suo, Rui-Nuo Jia, Yong-Qiang Li, Xiao-Dong Peng, Si-Chen Wang, Ai-Ai Yu, Jie Xie, Miao-Zhen Qiu, Rui-Hua Xu
You can read the Full Article in the Nature Medicine.
More posts featuring Ilyas Sahin on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023